Lung Cancer

Adding pembrolizumab (Keytruda) to first-line chemotherapy improves response and survival rates among patients with previously-untreated advanced PD-L1-positive non-small cell lung cancer.

The use of the PD1 inhibitor nivolumab appeared to be feasible and safe in a small study of patients with untreated, stage I–IIIa non–small-cell lung cancer.

Patients diagnosed with early-stage lung cancer who are also diagnosed with depression have an increased risk of mortality, according to a prospective, observational study.

The US Food and Drug Administration has approved a plasma sample label extention for the T790M companion diagnostic blood test, cobas® Mutation Test v2.

Combining two cancer immunotherapies to target both the interleukin 10 (IL-10) and programmed cell death protein 1 (PD-1) receptors has yielded promising early results for some patients with renal cell carcinoma and non-small cell lung cancer.

Researchers in Texas are now reporting they have developed drug-loaded synthetic nanoparticles that can distinguish lung cancer cells from healthy cells.

A 34-year-old woman presents with a coin lesion in the right upper lobe of the lung. What is your diagnosis?

US soldiers and veterans will be at the forefront of a new nationwide integrated proteogenomic lung tumor screening program aimed at boosting enrollment in clinical trials and hastening the development of targeted anticancer therapies.

Although the overall incidence of programmed cell death 1 (PD-1) inhibitor-related pneumonitis is rare, the serious adverse event may occur more commonly in certain solid tumor types like non–small-cell lung cancer and renal cell carcinoma.

Researchers from China have discovered a way to offset the brain complications of leptomeningeal metastases in patients with non-small cell lung cancer.

Automated computer analysis of pathology slide images can more accurately predict lung cancer patient prognosis than can human pathologists, according to researchers at the Stanford University School of Medicine.

In a phase III trial, Opdivo (nivolumab) did not meet its primary endpoint, a disappointment to researchers and patients.

Immune checkpoint inhibitors have changed the treatment paradigm for patients with lung cancer, bringing about the most promising outcomes we have seen in a long time.

Immune checkpoint inhibitors are a reality for the treatment of patients with NSCLC, and if approved for SCLC, would be a treatment breakthrough we have not seen for decades.

The combination of pemetrexed and gefitinib offered improved progression-free survival in East Asian patients with advanced nonsquamous NSCLC and activating EGFR mutations.

Transgenomic, Inc. has announced the commercial availability of assays to detect EGFR C797S mutation, a mechanism of acquired lung tumor resistance to third-generation tyrosine kinase inhibitors in non-small cell lung cancer.

A trial showed that KRAS wild-type NSCLC patients fare better with regimens containing erlotinib, while KRAS-mutated patients had better outcomes without erlotinib.

Virginia Cancer Specialists reported they have enrolled the first patient in a new advanced lung cancer clinical trial for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.

Prescribing nivolumab only to patients with programmed cell death ligand 1-positive (PD-L1+) tumors improves its cost-effectiveness.

ALK-targeting agents such as crizotinib may work most effectively in lung cancer patients with ALK variant 1.

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.

Newly discovered microRNAs harbored by tumor-initiating cancer stem cells, drive tumorigenesis and metastasis of non-small cell lung cancer.

New steps are now being taken to revise molecular testing guidelines in an effort to improve patient selection and optimize the use of targeted therapies in lung cancer patients.

Two parts of a phase I trial found that nivolumab could be a good first-line treatment option for patients with advanced non–small-cell lung cancer.

A new combination therapy is showing promise for treating advanced solid tumors and may especially be beneficial in patients with recurrent or metastatic triple-negative breast cancer.

The FGFR inhibitor dovitinib showed modest efficacy in a phase II trial of patients with pretreated, advanced squamous cell lung cancer with FGFR1 amplification

Inflammatory arthritis and sicca syndrome appear to be immune-related adverse events among some patients undergoing cancer treatment with the immune checkpoint inhibitors nivolumab and ipilimumab.

The use of hemithoracic pleural IMRT after chemotherapy could become part of a new lung-sparing therapy in patients with malignant pleural mesothelioma.

Molecular imaging of tumor glucose metabolism might be a prognostic biomarker of NSCLC responses to the investigational immunotherapy agent atezolizumab.